Multi-institutional Patient-level Comparison of Decipher Genomic Classifier and Artera Multimodal Artificial Intelligence (MMAI) in Prostate Cancer
- Journal
- Clinical cancer research : an official journal of the American Association for Cancer Research (Q1)
- Published
- 8 October 2026
- Study design
- Unclassified
- Evidence level
- Level 5, Expert Opinion (CEBM 5)
- Authors
- Boon Hao Hong, Adeniyi A Olabumuyi, Shuang G Zhao, Purvish Trivedi, Ryan Putney, Esther Katende, et al.
- PMID
- 42848319
- DOI
- 10.1158/1078-0432.CCR-26-2269
Why clinicians should know about it
- Picked for Urology (paper of the day, 10 October 2026): Direct comparison of Decipher and ArteraAI prognostic tools in prostate
Abstract
IMPORTANCE: The Decipher Prostate Genomic Classifier (GC) and ArteraAI Multimodal Artificial Intelligence (MMAI) platform are widely used prognostic tools for localized prostate cancer (PCa), yet no direct comparison has been performed within the same patient cohort. METHODS: We sought to evaluate the concordance and prognostic value of GC and MMAI across multi-institutional cohorts totaling 688 patients with localized and oligometastatic PCa. These included populations enriched for African American and East Asian patients. GC and MMAI scores were stratified into risk groups based on specimen type (biopsy or radical prostatectomy (RP)). The primary endpoint was distant metastasis-free survival (DMFS), measured from diagnosis to last follow-up or event. RESULTS: GC and MMAI scores were significantly correlated across multiple cohorts. In Moffitt RP, biopsy, and NCCS cohorts, both MMAI and GC were prognostic alone and after adjusting for clinical variables. Multivariable analysis including both biomarkers and clinical variables showed that MMAI was significant even accounting for GC in Moffitt RP, and borderline in Moffitt biopsy. Analysis of concordant/discordant cases showed that patients who were high-risk for both GC and MMAI did qualitatively worse. In pathway analysis, concordance with GC and MMAI was high for Moffitt RP and oligometastatic patients. Across both biopsy cohorts, while most biological pathways were concordant, there were consistent discordant signaling, metabolic, and DNA repair pathways. CONCLUSIONS: In the first direct patient-level comparison of GC and MMAI in PCa, these biomarkers were found to demonstrate moderate correlation, and both biomarkers demonstrated prognostic value across diverse populations and disease states.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.